181 related articles for article (PubMed ID: 34995690)
21. Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study.
El-Husseiny WM; El-Sayed MA; Abdel-Aziz NI; El-Azab AS; Ahmed ER; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):507-518. PubMed ID: 29455554
[TBL] [Abstract][Full Text] [Related]
22. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
[TBL] [Abstract][Full Text] [Related]
25. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
Yassen AS; Elshihawy HE; Said MM; Abouzid KA
Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
[TBL] [Abstract][Full Text] [Related]
26. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
27. Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies.
Ahmed MF; Santali EY; Mohi El-Deen EM; Naguib IA; El-Haggar R
Bioorg Chem; 2021 Jan; 106():104473. PubMed ID: 33243490
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a novel series of substituted quinolines acting as anticancer agents and selective EGFR blocker: Molecular docking study.
Kumar CBP; Raghu MS; Prathibha BS; Prashanth MK; Kanthimathi G; Kumar KY; Parashuram L; Alharthi FA
Bioorg Med Chem Lett; 2021 Jul; 44():128118. PubMed ID: 34015505
[TBL] [Abstract][Full Text] [Related]
29. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
31. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors.
Desai S; Desai V; Shingade S
Bioorg Chem; 2020 Jan; 94():103382. PubMed ID: 31662214
[TBL] [Abstract][Full Text] [Related]
32. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
[TBL] [Abstract][Full Text] [Related]
33. Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors.
Xiao Z; Chu C; Zhou L; Zhou Z; Zhang Q; Yang F; Yang Z; Zheng P; Xu S; Zhu W
Bioorg Med Chem; 2020 Oct; 28(19):115669. PubMed ID: 32912435
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW
Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233
[No Abstract] [Full Text] [Related]
35. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
37. Targeting EGFR tyrosine kinase: Synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives.
Mokhtar AM; El-Messery SM; Ghaly MA; Hassan GS
Bioorg Chem; 2020 Nov; 104():104259. PubMed ID: 32919134
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.
Abbas HS; Abd El-Karim SS
Bioorg Chem; 2019 Aug; 89():103035. PubMed ID: 31200286
[TBL] [Abstract][Full Text] [Related]
39. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
